Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab^†.

ABSTRACT:

Background

The use of bevacizumab for recurrent glioblastoma is controversial. Here we show data on patients who responded to bevacizumab, then stopped bevacizumab for any reason other than progression and were rechallenged with bevacizumab at the time of subsequent progression.

Methods

This retrospective study included 28 patients, classified in 2 cohorts: those for whom the first exposure to bevacizumab (BEV-1) was first-line treatment for newly diagnosed glioblastoma (Bev-F; N = 12) and those for whom BEV-1 was second- or third-line treatment for recurrent disease after standard treatment (Bev-S; N = 16).

Results

All patients received standard radiotherapy plus temozolomide. Bev-F patients also received concomitant bevacizumab. All 28 patients receive

SUBMITTER: Balana C 

PROVIDER: S-EPMC6655406 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature